Penumbra agreed to be acquired by Boston Scientific Corporation for approximately $14.5 billion, with each share valued at $374 and closing expected in early 2027. Revenue for the nine months ended September 30, 2026 increased 15.4% to $1,174.9 million.
PEN · Penumbra Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Penumbra Inc reported third-quarter 2026 revenue of $410.1 million, up 15.6%, global thrombectomy revenue of $279.2 million, up 18.1%, and net income of $42.3 million; pending acquisition by Boston Scientific Corporation led it to withhold full year 2026 guidance.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PEN
this stock
Penumbra Inc
|
$12.58B | +2.6% | +17.5% | 80.4 | 6.1% |
|
ABT
Abbott Laboratories
|
$181.35B | -16.4% | +5.7% | 39.1 | 1.1% |
|
MDT
Medtronic plc
|
$130.88B | +6.5% | +8.4% | 25.2 | 1.8% |
|
SYK
Stryker Corp
|
$120.88B | -9.7% | +11.2% | 33.8 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.37B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 29, 2026
- This year
- 15
Penumbra agreed to be acquired by Boston Scientific Corporation for approximately $14.5 billion, with each share valued at $374 and closing expected in early 2027. Revenue for the nine months ended September 30, 2026 increased 15.4% to $1,174.9 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PEN | -0.7% | -1.6% | +0.1% | +0.1% | +2.6% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +1.6% | +3.2% | +3.0% | +3.1% | -4.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.